Given that EGFR has recently been identified as a biomarker at the adenoma stage for more aggressive CRC progression (Williet et al, 2017), our findings suggest that there could also be clinical benefit in assessing LGR5 expression at this early stage in order to stratify those patients who may respond best to EGFR therapy. This evidence concerns the gene EGFR and colorectal carcinoma.